EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease

Fateh Bazerbachi, Eric J. Vargas, Reem Matar, Andrew C. Storm, Taofic M. Mounajjed, Mark D. Topazian, Michael J. Levy, Vinay Chandrasekhara, Barham K. Abu Dayyeh

Research output: Contribution to journalArticle

Abstract

Background and Aims: Diagnostic tools for nonalcoholic fatty liver disease (NAFLD) detection and prognostication are limited, with histology remaining the criterion standard. We evaluated the feasibility and safety of EUS-guided liver biopsy (EUS-LB) sampling in NAFLD staging. Methods: In a prospective cohort of NAFLD patients with steatohepatitis and early liver fibrosis based on magnetic resonance elastography (MRE), EUS-LB sampling procedures were performed using a 22-gauge fork-tip core biopsy needle. Samples were evaluated by a blinded pathologist. Total aggregate sample length (TASL), number of complete portal triads, ability to calculate NAFLD activity score, ability to stage liver fibrosis, and ability to provide enough core liver tissue for lipidomics analysis were evaluated. Performance of EUS-LB sampling was compared with MRE. Results: Forty-one EUS-LB samples were obtained. The median TASL was 2.4 cm (interquartile range, 2.00-2.75). The median number of complete portal triads per TASL was 26 (interquartile range, 7-62). Of the samples, 100% were adequate to convey NAFLD activity score and fibrosis stage. All samples provided enough core liver tissue to allow the application of lipidomics testing. A significant positive linear association between EUS-LB sampling–detected fibrosis and MRE-detected fibrosis was observed (r =.469, P <.005). Compared with MRE, EUS-LB sampling established early fibrosis in 13 cases that MRE classified as normal. EUS-LB sampling–related adverse events occurred in 7% and were restricted to postprocedural pain. Conclusions: EUS-LB sampling is a viable technique for full NAFLD evaluation and may be superior to MRE in establishing the diagnosis of nonalcoholic steatohepatitis with early fibrosis. (Clinical trial registration number: NCT02880189.)

Original languageEnglish (US)
JournalGastrointestinal endoscopy
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Needles
Elasticity Imaging Techniques
Biopsy
Liver
Fibrosis
Aptitude
Liver Cirrhosis
Non-alcoholic Fatty Liver Disease
Large-Core Needle Biopsy
Fatty Liver
Histology
Clinical Trials
Safety
Pain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle : a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease. / Bazerbachi, Fateh; Vargas, Eric J.; Matar, Reem; Storm, Andrew C.; Mounajjed, Taofic M.; Topazian, Mark D.; Levy, Michael J.; Chandrasekhara, Vinay; Abu Dayyeh, Barham K.

In: Gastrointestinal endoscopy, 01.01.2019.

Research output: Contribution to journalArticle

@article{fd8b39d75fd3463f8b3e5b207092979f,
title = "EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease",
abstract = "Background and Aims: Diagnostic tools for nonalcoholic fatty liver disease (NAFLD) detection and prognostication are limited, with histology remaining the criterion standard. We evaluated the feasibility and safety of EUS-guided liver biopsy (EUS-LB) sampling in NAFLD staging. Methods: In a prospective cohort of NAFLD patients with steatohepatitis and early liver fibrosis based on magnetic resonance elastography (MRE), EUS-LB sampling procedures were performed using a 22-gauge fork-tip core biopsy needle. Samples were evaluated by a blinded pathologist. Total aggregate sample length (TASL), number of complete portal triads, ability to calculate NAFLD activity score, ability to stage liver fibrosis, and ability to provide enough core liver tissue for lipidomics analysis were evaluated. Performance of EUS-LB sampling was compared with MRE. Results: Forty-one EUS-LB samples were obtained. The median TASL was 2.4 cm (interquartile range, 2.00-2.75). The median number of complete portal triads per TASL was 26 (interquartile range, 7-62). Of the samples, 100{\%} were adequate to convey NAFLD activity score and fibrosis stage. All samples provided enough core liver tissue to allow the application of lipidomics testing. A significant positive linear association between EUS-LB sampling–detected fibrosis and MRE-detected fibrosis was observed (r =.469, P <.005). Compared with MRE, EUS-LB sampling established early fibrosis in 13 cases that MRE classified as normal. EUS-LB sampling–related adverse events occurred in 7{\%} and were restricted to postprocedural pain. Conclusions: EUS-LB sampling is a viable technique for full NAFLD evaluation and may be superior to MRE in establishing the diagnosis of nonalcoholic steatohepatitis with early fibrosis. (Clinical trial registration number: NCT02880189.)",
author = "Fateh Bazerbachi and Vargas, {Eric J.} and Reem Matar and Storm, {Andrew C.} and Mounajjed, {Taofic M.} and Topazian, {Mark D.} and Levy, {Michael J.} and Vinay Chandrasekhara and {Abu Dayyeh}, {Barham K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.gie.2019.08.006",
language = "English (US)",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle

T2 - a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease

AU - Bazerbachi, Fateh

AU - Vargas, Eric J.

AU - Matar, Reem

AU - Storm, Andrew C.

AU - Mounajjed, Taofic M.

AU - Topazian, Mark D.

AU - Levy, Michael J.

AU - Chandrasekhara, Vinay

AU - Abu Dayyeh, Barham K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aims: Diagnostic tools for nonalcoholic fatty liver disease (NAFLD) detection and prognostication are limited, with histology remaining the criterion standard. We evaluated the feasibility and safety of EUS-guided liver biopsy (EUS-LB) sampling in NAFLD staging. Methods: In a prospective cohort of NAFLD patients with steatohepatitis and early liver fibrosis based on magnetic resonance elastography (MRE), EUS-LB sampling procedures were performed using a 22-gauge fork-tip core biopsy needle. Samples were evaluated by a blinded pathologist. Total aggregate sample length (TASL), number of complete portal triads, ability to calculate NAFLD activity score, ability to stage liver fibrosis, and ability to provide enough core liver tissue for lipidomics analysis were evaluated. Performance of EUS-LB sampling was compared with MRE. Results: Forty-one EUS-LB samples were obtained. The median TASL was 2.4 cm (interquartile range, 2.00-2.75). The median number of complete portal triads per TASL was 26 (interquartile range, 7-62). Of the samples, 100% were adequate to convey NAFLD activity score and fibrosis stage. All samples provided enough core liver tissue to allow the application of lipidomics testing. A significant positive linear association between EUS-LB sampling–detected fibrosis and MRE-detected fibrosis was observed (r =.469, P <.005). Compared with MRE, EUS-LB sampling established early fibrosis in 13 cases that MRE classified as normal. EUS-LB sampling–related adverse events occurred in 7% and were restricted to postprocedural pain. Conclusions: EUS-LB sampling is a viable technique for full NAFLD evaluation and may be superior to MRE in establishing the diagnosis of nonalcoholic steatohepatitis with early fibrosis. (Clinical trial registration number: NCT02880189.)

AB - Background and Aims: Diagnostic tools for nonalcoholic fatty liver disease (NAFLD) detection and prognostication are limited, with histology remaining the criterion standard. We evaluated the feasibility and safety of EUS-guided liver biopsy (EUS-LB) sampling in NAFLD staging. Methods: In a prospective cohort of NAFLD patients with steatohepatitis and early liver fibrosis based on magnetic resonance elastography (MRE), EUS-LB sampling procedures were performed using a 22-gauge fork-tip core biopsy needle. Samples were evaluated by a blinded pathologist. Total aggregate sample length (TASL), number of complete portal triads, ability to calculate NAFLD activity score, ability to stage liver fibrosis, and ability to provide enough core liver tissue for lipidomics analysis were evaluated. Performance of EUS-LB sampling was compared with MRE. Results: Forty-one EUS-LB samples were obtained. The median TASL was 2.4 cm (interquartile range, 2.00-2.75). The median number of complete portal triads per TASL was 26 (interquartile range, 7-62). Of the samples, 100% were adequate to convey NAFLD activity score and fibrosis stage. All samples provided enough core liver tissue to allow the application of lipidomics testing. A significant positive linear association between EUS-LB sampling–detected fibrosis and MRE-detected fibrosis was observed (r =.469, P <.005). Compared with MRE, EUS-LB sampling established early fibrosis in 13 cases that MRE classified as normal. EUS-LB sampling–related adverse events occurred in 7% and were restricted to postprocedural pain. Conclusions: EUS-LB sampling is a viable technique for full NAFLD evaluation and may be superior to MRE in establishing the diagnosis of nonalcoholic steatohepatitis with early fibrosis. (Clinical trial registration number: NCT02880189.)

UR - http://www.scopus.com/inward/record.url?scp=85073024046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073024046&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2019.08.006

DO - 10.1016/j.gie.2019.08.006

M3 - Article

C2 - 31437454

AN - SCOPUS:85073024046

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

ER -